How do I perform a digital rectal examination (DRE) on a man aged ≥50 years (or any male with urinary or pelvic symptoms, family history of prostate disease, or abnormal prostate-specific antigen (PSA) results), including consent, positioning, technique, and contraindications?

How to Perform a Digital Rectal Examination for Prostate Assessment

Obtain Informed Consent

Before performing a DRE, explain to the patient that you will insert a gloved, lubricated finger into the rectum to feel the prostate gland for size, symmetry, nodules, or areas of firmness that may suggest cancer or enlargement. 1 Emphasize that while the examination is uncomfortable, it takes less than 30 seconds and provides critical information that PSA testing alone cannot detect—specifically, 31% of men with prostate cancer and an abnormal DRE have normal age-specific PSA values. 2

Patient Positioning

Position the patient in one of three ways:

• Left lateral decubitus (lying on left side, knees drawn to chest)—most common in office settings 1
• Standing, bent forward at waist with elbows resting on examination table 1
• Lithotomy position (supine with knees flexed)—less commonly used for prostate examination 1

The left lateral position provides the best access to palpate the entire posterior and lateral surfaces of the prostate. 1

Examination Technique

Preparation

• Apply generous water-based lubricant to your gloved index finger 1
• Warn the patient before insertion to reduce sphincter spasm 1

Insertion and Initial Assessment

• Gently insert your lubricated index finger through the anal sphincter, advancing 3–4 cm until you palpate the prostate on the anterior rectal wall 1
• First assess anal sphincter tone and rectal wall for masses or irregularities 1

Prostate Palpation

Systematically evaluate the following characteristics 1:

Size: Estimate prostate volume in grams or describe as normal, moderately enlarged, or markedly enlarged. Note that DRE consistently underestimates true prostate size—if the gland feels large on DRE, ultrasound will confirm even greater enlargement. 1, 3

Symmetry: Compare the right and left lobes. Asymmetry between lobes suggests focal pathology and warrants biopsy regardless of PSA level. 3

Consistency: A normal prostate feels rubbery, similar to the thenar eminence of your hand when making a fist. 1

Surface characteristics:

• Nodules—discrete, firm lumps are the most concerning finding for malignancy 3
• Induration—areas of stony hardness or increased firmness 3
• Irregularity—loss of smooth contour 1

Mobility: The prostate should move slightly with palpation. Fixation to surrounding structures suggests locally advanced cancer. 3

Tenderness: Marked tenderness suggests acute prostatitis (a contraindication to vigorous examination). 1

Median Sulcus

Palpate the midline groove separating the two lobes—obliteration of this sulcus may indicate enlargement or infiltration. 1

What Constitutes an Abnormal DRE

Any of the following findings mandate immediate referral for prostate biopsy, regardless of PSA level 3:

• Discrete nodules or focal induration 3
• Asymmetry between the right and left lobes 3
• Areas of increased firmness compared to surrounding tissue 3
• Any change from a prior examination in men on active surveillance 3

In a contemporary biopsy cohort, 44% of men diagnosed with prostate cancer had an abnormal DRE, and 14% had an isolated DRE abnormality as their only indication for biopsy. 2 Critically, DRE detected prostate cancer in 31% of men with normal age-specific PSA values. 2

Absolute Contraindications

• Acute prostatitis—vigorous palpation can precipitate bacteremia 1
• Patient refusal after informed discussion 1

Relative caution is warranted in men with severe hemorrhoids or anal fissures, but these are not absolute contraindications. 1

Clinical Context and Integration with PSA

DRE should never be used as a stand-alone screening test but must be performed in conjunction with serum PSA measurement. 1 The two tests are complementary, not interchangeable:

• DRE has a sensitivity of 44% and specificity of 68% for detecting prostate cancer 2
• PSA is more sensitive than DRE, but DRE identifies 14% of cancers that PSA alone would miss 2
• When DRE and PSA are both abnormal, the positive predictive value for cancer rises to 75% 4

Documentation

Record the following in the medical record 1:

• Prostate size (estimated grams or descriptive: small, normal, moderately enlarged, markedly enlarged)
• Symmetry (symmetric vs. asymmetric; if asymmetric, specify which lobe)
• Consistency (soft, rubbery/normal, firm, hard/indurated)
• Surface (smooth vs. nodular; if nodular, describe location and size)
• Median sulcus (present vs. obliterated)
• Mobility (mobile vs. fixed)
• Tenderness (present vs. absent)
• Overall impression: normal vs. abnormal

Common Pitfalls to Avoid

• Skipping DRE in men who find it uncomfortable—the American Cancer Society explicitly states that PSA alone is acceptable only when DRE is an obstacle to testing, but this should be a patient-driven decision after informed discussion, not a provider convenience. 1

• Relying solely on PSA—31% of men with prostate cancer and an abnormal DRE have normal PSA values. 2

• Failing to refer men with abnormal DRE and normal PSA—an abnormal DRE is an independent indication for biopsy regardless of PSA level. 3, 5

• Performing DRE without skill training—DRE should be performed by healthcare workers skilled in detecting subtle abnormalities of the prostate. 1 If you are inexperienced, seek supervision or refer to urology.

• Assuming a normal DRE rules out cancer—DRE has only 44% sensitivity, meaning it misses more than half of prostate cancers. 2 Always combine with PSA testing.

Age-Specific Screening Recommendations

DRE should be offered as part of prostate cancer screening 1:

• Age 50 for average-risk men with ≥10-year life expectancy 1
• Age 45 for African American men or men with a first-degree relative diagnosed before age 65 1
• Age 40 for men with multiple first-degree relatives diagnosed before age 65 1

Discontinue routine DRE screening at age 70 unless the patient is exceptionally healthy with minimal comorbidity, prior elevated PSA, and life expectancy >10–15 years. 1